Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY

Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions

As of 2019, the CA-SFM (Comité de l'Antibiogramme de la Société Française de Microbiologie) recommends that the letter "I" or the term "intermediate" on antibiotic antibiograms. Instead, it is recommended that the term "sensible à forte posologie" or "SFP". These recommendations have been in place since 21/01/2022 at Nancy University Hospital.

Pseudomonas aeruginosa is the bacterium most affected by this change, as it has a high proportion of "high dosage" antibiotics.

Staphylococcus aureus is the most widely isolated bacterium, and also impacted by the change in antibiotic susceptibility testing.

The aim of this change in recommendations is to guarantee the efficacy of the proposed molecules.

Main objective Evaluate the impact of the change in antibiogram recommendations in samples positive for Pseudomonas aeruginosa and Staphylococcus aureus on antibiotic therapy (prescribed dosage)

Secondary objectives

  • Evaluate the impact of changing the way antibiograms in Pseudomonas aeruginosa and Staphylococcus aureus on antibiotic therapy (molecule prescribed).
  • Evaluate the impact of changing the way antibiograms on antibiotic therapy (molecule and dosage prescribed), depending on the strain identified (Pseudomonas aeruginosa or Staphylococcus aureus).
  • Describe the impact of changing antibiograms in Pseudomonas aeruginosa and Staphylococcus aureus on antibiotic therapy (molecule and dosage prescribed) by department.
Am I Eligible? Learn more

Highlighted Text Block

You can use content blocks to arrange your articles, large texts, instructions. Combine these blocks with media blocks to add illustrations and video tutorials. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links.

Diabetes

What is Diabetes?
A large percentage of viewers are on mobile devices, so keep it short and to the point. Have you ever noticed how long a 5 sentence paragraph looks on a smart phone? If you read it via desktop/laptop, you realize it is really not that much information. A suggestion is to plan on “marrying” the two and keep the chatter down. Conversely, don’t sacrifice the “meat and potatoes” of what you’re trying to convey; this will help to keep the organic SEO strong.
What causes Diabetes?
Viewers need to be given a direction every now and then. Use your headers to draw the eye where you want it. Imagine the website as a term paper and your outline will guide your structure. Focus broad topics on the main headers and help guide the viewer down the right path! Appropriately introducing call-to-action buttons also helps with guiding the reader and connecting content writing with your website’s goal.
How is Diabetes treated?
Here are a few website content writing tips to make sure your website content gets the attention it deserves • Know your audience • Write short, simple sentences – Nix the jargon – Mix up your word choice • Make text scannable • Incorporate multimedia Capturing reader’s interests with good website content and information can be challenging. Most visitors will spend just a few seconds on a webpage, before deciding what to do next. Therefore, good website writing is the key to beating these odds.
More information about Diabetes
National Diabetes Foundation National Diabetes Foundation – Support Network American Academy of Diabetes International Diabetes Council International Federation of Diabetes Associations

Call 1800-9860-568 now to find out if you are eligible.

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
content image
Diabetes
A short sentence to introduce what to expect in the about condition section
Learn more
The Study
A short sentence to introduce what to expect in the about condition section
Learn more
About Clinical Trials
A short sentence to introduce what to expect in the about condition section
Learn more

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
Am I eligible? Learn More
content image
content image

Are you a patient with moderate to severe plaque psoriasis?

Have you treated your condition with adalimumab (Humira®) and did it become less effective on your plaque psoriasis within the last 6 months? If so, you may be eligible for a clinical research study with etanercept (Enbrel®) which is also approved for moderate to severe plaque psoriasis. Qualified participants will receive an initial consultation, study-related examinations, and study medication.
Am I eligible? Learn More
content image